Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H31N3O3 |
| Molecular Weight | 373.4891 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(C=C1)N(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)C(=O)N2CCN
InChI
InChIKey=ZGTYTFYRCIRWBL-HYVNUMGLSA-N
InChI=1S/C21H31N3O3/c1-13(2)16-7-5-14(3)11-17(16)20(25)24-18-8-6-15(27-4)12-19(18)23(10-9-22)21(24)26/h6,8,12-14,16-17H,5,7,9-11,22H2,1-4H3/t14-,16+,17-/m1/s1
| Molecular Formula | C21H31N3O3 |
| Molecular Weight | 373.4891 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 10:47:45 GMT 2025
by
admin
on
Wed Apr 02 10:47:45 GMT 2025
|
| Record UNII |
70FBL3TX3E
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
44137358
Created by
admin on Wed Apr 02 10:47:45 GMT 2025 , Edited by admin on Wed Apr 02 10:47:45 GMT 2025
|
PRIMARY | |||
|
D-3263 (FREE BASE)
Created by
admin on Wed Apr 02 10:47:45 GMT 2025 , Edited by admin on Wed Apr 02 10:47:45 GMT 2025
|
PRIMARY | Official Title: A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid TumorsPurpose: This is a Phase 1, dose escalation study evaluating safety and pharmacokinetics of enteric coated D-3263 HCl in subjects with advanced solid tumors. | ||
|
947257-66-1
Created by
admin on Wed Apr 02 10:47:45 GMT 2025 , Edited by admin on Wed Apr 02 10:47:45 GMT 2025
|
PRIMARY | |||
|
70FBL3TX3E
Created by
admin on Wed Apr 02 10:47:45 GMT 2025 , Edited by admin on Wed Apr 02 10:47:45 GMT 2025
|
PRIMARY | |||
|
C162345
Created by
admin on Wed Apr 02 10:47:45 GMT 2025 , Edited by admin on Wed Apr 02 10:47:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Dendreon Corporation; Class: Antineoplastic, Small molecule; Mechanism of Action: Apoptosis stimulant, TRPM8 protein stimulant; Highest Development Phases: Suspended for Benign prostatic hyperplasia, Solid tumours; Most Recent Events: 31 Dec 2013 Suspended - Phase-I for Solid tumours in USA (PO), 31 Dec 2013 Suspended - Preclinical for Benign prostatic hyperplasia in USA (PO), 01 Dec 2011 Dendreon completes its phase I trial for Solid tumours in USA (NCT00839631)
|
